Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...